During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...
Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback